Budget impact analysis of cenobamate, a novel adjunctive therapy for the treatment of drug resistant focal onset seizures, from the Belgian healthcare payer perspective
The savings at medical cost level fully offset the impact of cenobamate on the drug budget, leading to an overall healthcare budget saving of -€8,105,616 for NIHDI. This favourable outcome is largely due to cenobamate's high efficacy reflected in its high response rate and significant effect on reducing seizure frequency.
Authors
- Kristl E.J. Vonck (ORCID: https://orcid.org/0000-0002-2671-2650)
- Sarah Weckhuysen (ORCID: https://orcid.org/0000-0003-2878-1147)
- Lynn Van den Bergh
- Olivier Bodart (ORCID: https://orcid.org/0000-0003-1188-5484)
- Ann Tanghe
- Caroline Verdonck (ORCID: https://orcid.org/0000-0002-3993-0075)
- Britt Callebaut
- Benjamin Legros (ORCID: https://orcid.org/0000-0002-9938-7457)
Institutions
- HOGENT University of Applied Sciences and Arts (BE)
- University of Liège (BE)
- Ghent University Hospital (BE)
- Erasmus Hospital (BE)
- Antwerp University Hospital (BE)
- Angelini Pharma (Italy) (IT)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2025-06-17
- DOI
- https://doi.org/10.1080/13696998.2025.2520182
- Citations
- 1
- Primary Topic
- Epilepsy research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.47